Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Naveed, Chowhan"'
Autor:
Ziping Wang, Petros Nikolinakos, Lyudmila Bazhenova, Naveed Chowhan, Chao Hua Chiu, Nong Yang, Yuan Chen, Her Shyong Shiah, David Berz, You Lu, Maurice Willis, Chin Chou Wang, Keisuke Shirai, Renhua Guo, Gee-Chen Chang, Te Chun Hsia, Shun Lu, Wu Chou Su, James Chih-Hsin Yang, Mohammad Jahanzeb, Jianying Zhou, Hong Jian, Hongming Pan, Cheng-Ta Yang, D. Ross Camidge, Ajit Maniam, Nehal Masood, Jianhua Chen, Jian Fang
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(12)
Introduction Almonertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations. This first-in-human trial aimed to evaluate the safety, efficacy, and pharm
Autor:
Yuan Chen, Cheng-Ta Yang, Nong Yang, Renhua Guo, David Berz, Gee-Chen Chang, You Lu, Nehal Masood, James Chih-Hsin Yang, Petros Nikolinakos, Maurice Willis, Keisuke Shirai, Mohammad Jahanzeb, Wu Chou Su, Wang Cc, Chao-Hua Chiu, Jianying Zhou, Te Chun Hsia, Ziping Wang, Shun Lu, Lyudmila Bazhenova, Hong Jian, D. Ross Camidge, Ajit Maniam, Jianhua Chen, Jian Fang, Her-Shyong Shiah, Hongming Pan, Naveed Chowhan
Publikováno v:
SSRN Electronic Journal.
Background: HS-10296 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against both EGFR-sensitizing and T790M-resistant mutations. This first-in-human trial aimed to evaluate the safety, tolerability, ph
Autor:
Shirish M. Gadgeel, Ben Mitchell, Ronald H. Yanagihara, Roel P. Funke, Heather A. Wakelee, Nandagopal Vrindavanam, M. Catherine Pietanza, Vincent A. Miller, Nathan A. Pennell, Primo N. Lara, John Cho, Naveed Chowhan, Thomas J. Lynch
Publikováno v:
Journal of Thoracic Oncology. 7:219-226
Introduction Although patients with non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) activating mutations commonly experience significant regressions when treated with erlotinib or gefitinib, they uniform
Autor:
R. Camidge, Naveed Chowhan, Renhua Guo, Ajit Maniam, J. Zhou, Chun Chih Chiu, Shun Lu, W. Su, Mohammad Jahanzeb, Hongming Pan, Nehal Masood, T. Hsia, David Berz, H. Shiah, Zhijie Wang, Yilu Lu, Maurice Willis, Keisuke Shirai, Jianhua Chen, C.-T. Yang, Jian Fang, G-C. Chang, Nong Yang, Yuan Chen, Lyudmilla Bazhenova, J.C.-H. Yang, Petros Nikolinakos, Wang Cc
Publikováno v:
Journal of Thoracic Oncology. 13:S485
Autor:
Ronald Beaton, Stephanie Fertman, Afif Iliya, Mehender Pampati, Raphael P. Davis, Naveed Chowhan, Orlando Alvarez, Allen G. Meek, Stefan Madajewicz, Clemente Roque, George W. Tyson
Publikováno v:
Cancer. 67:2844-2849
Chemotherapy for tumors of the central nervous system has a limited efficacy presumably because of restricted blood-brain barrier permeability. The advantage of regional intra-arterial administration of anticancer drugs is an increased uptake during
Autor:
Stefan Madajewicz, Alex Braun, Harold Atkins, Affif Iliya, Patricia Roche, Arafat Tfayli, Allen Meek, Magdy Shady, Naveed Chowhan, Corazon Cabahug, Raphael Davis, Walter Wolf, Clemente Roque, James Manzione, N P Patricia Hentschel
Publikováno v:
Cancer. 88(10)
BACKGROUND High grade astrocytomas account for approximately 40% of all primary brain tumors. The median survival is approximately 8–10 months for patients with glioblastoma multiforme and 36 months for patients with anaplastic astrocytoma. The res
Autor:
Patricia Burns, Nabil Hagag, William Lipera, Naveed Chowhan, Patricia Hentschel, John J. Fiore, Daniele Matei, Hosein Zarrabi, Louis Avvento, Stefan Madajewicz
Publikováno v:
Cancer. 76(8)
Background. Approximately 140,000 new cases of colorectal carcinoma will be diagnosed in 1995 in the United States, and more than one-third of these patients will die from progressive disease. Despite the modest improvement in response rate with chem
Autor:
N. Vrindavanam, Nathan A. Pennell, Primo N. Lara, John Cho, Heather A. Wakelee, Naveed Chowhan, Vincent A. Miller, Thomas J. Lynch, R. Yanagihara, Daniel B. Costa
Publikováno v:
Journal of Clinical Oncology. 26:8028-8028
8028 Background: XL647 is an orally bioavailable small molecule inhibitor of RTKs (EGFR, HER2, and VEGFR2) involved in tumor growth, angiogenesis, and metastasis. First-generation EGFR TKIs are act...
Publikováno v:
Supportive Care in Cancer; Nov2007, Vol. 15 Issue 11, p1285-1291, 7p
Autor:
Naveed Chowhan, Zarrabi Mh
Publikováno v:
American Journal of Hematology. 41:144-144